Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality

Antoinette Moran, Jordan Dunitz, Brandon Nathan, Asad Saeed, Bonnie Holme, William Thomas, Antoinette Moran, Jordan Dunitz, Brandon Nathan, Asad Saeed, Bonnie Holme, William Thomas

Abstract

Objective: Cystic fibrosis (CF)-related diabetes (CFRD) diagnosis and management have considerably changed since diabetes was first shown to be associated with a poor prognosis in subjects with CF. Current trends in CFRD prevalence, incidence, and mortality were determined from a comprehensive clinical database.

Research design and methods: Data were reviewed from 872 CF patients followed at the University of Minnesota during three consecutive intervals: 1992-1997, 1998-2002, and 2003-2008.

Results: CFRD is currently present in 2% of children, 19% of adolescents, and 40-50% of adults. Incidence and prevalence are higher in female subjects aged 30-39 years; otherwise, there are no sex differences. In younger individuals, CFRD without fasting hyperglycemia predominates, but fasting hyperglycemia prevalence rises with age. CFRD mortality has significantly decreased over time. From 1992-1997 to 2003-2008, mortality rate in female subjects dropped by >50% from 6.9 to 3.2 deaths per 100 patient-years and in male subjects from 6.5 to 3.8 deaths per 100 patient-years. There is no longer a sex difference in mortality. Diabetes was previously diagnosed as a perimorbid event in nearly 20% of patients, but of 61 patients diagnosed with diabetes during 2003-2008, only 2 died. Lung function but not nutritional status is still worse in CF patients with diabetes compared with those without diabetes. Nutritional status and pulmonary status are similar between patients without fasting hyperglycemia and those with fasting hyperglycemia.

Conclusions: Previously noted sex differences in mortality have disappeared, and the gap in mortality between CF patients with and without diabetes has considerably narrowed. We believe that early diagnosis and aggressive treatment have played a major role in improving survival in these patients.

Figures

Figure 1
Figure 1
Current prevalence of CFRD in the 527 patients actively followed at the University of Minnesota, 15 September 2008. A: CFRD total (■), CFRD with fasting hyperglycemia (▨), and CFRD without fasting hyperglycemia (□) by decade of age. B: CFRD total men (■) versus women (□) by decade of age. The number of total subjects (with and without diabetes) in each age-group is noted. *P = 0.02, men vs. women.
Figure 2
Figure 2
The University of Minnesota CFRD incidence per 100 patient-years by sex and age decade 2003–2008. Sample sizes for the incidence rates are shown below the figure.
Figure 3
Figure 3
The University of Minnesota CFRD and CF mortality per 100 patient-years by sex and age decade over three time periods: 2003–2008, 1998–2002, and 1992–1997. CF patients with diabetes (DM) are shown with solid lines, while CF patients without diabetes are shown with dashed lines. Zero rates estimated from

References

    1. Finkelstein SM, Wielinski CL, Elliott GR, Warwick WJ, Barbosa J, Wu SC, Klein DJ: Diabetes mellitus associated with cystic fibrosis. J Pediatr 1988; 112: 373– 377
    1. Milla CE, Billings J, Moran A: Diabetes is associated with dramatically decreased survival in female but not male subjects with cystic fibrosis. Diabetes Care 2005; 28: 2141– 2144
    1. Schwarzenberg SJ, Thomas W, Olsen TW, Grover T, Walk D, Milla CE, Moran A: Microvascular complications in cystic fibrosis-related diabetes. Diabetes Care 2007; 30: 1056– 1061
    1. Bismuth E, Laborde K, Taupin P, Velho G, Ribault V, Jennane F, Grasset E, Sermet I, De Buc J, Lenoir G, Robert J-J: Glucose tolerance and insulin secretion, morbidity and death in patients with CF. J Pediatr 2008; 152: 540– 545
    1. Cawood TJ, McKenna MJ, Gallagher CG, Smith D, Chung WY, Gibney J, O'Shea D: Cystic fibrosis-related diabetes in adults. Ir Med J 2006; 99: 83– 86
    1. Koch D, Rainisio M, Madessani U, Harms HK, Hodson ME, Mastella G, McKenzie SG, Navarro J, Strandvik B: Presence of cystic fibrosis-related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: data from the European Epidemiologic Registry of Cystic Fibrosis. Pediatr Pulmonol 2001; 32: 343– 350
    1. Lanng S, Thorsteinsson B, Nerup J, Koch C: Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis. Eur J Pediatr 1992; 151: 684– 687
    1. Marshall BC, Butler SM, Stoddard M, Moran AM, Liou TG, Morgan WJ: Epidemiology of cystic fibrosis-related diabetes. J Pediatr 2005; 146: 681– 687
    1. Moran A, Hardin D, Rodman D, Allen HF, Beall RJ, Borowitz D, Brunzell C, Campbell PW, Chesrown SE, Duchow C, Fink RJ, FitzSimmons SC, Hamilton N, Hirsch I, Howenstine MS, Klein DJ, Madhun Z, Pencharz PB, Quittner AL, Robbins MK, Schindler T, Schissel K, Schwarzenberg SJ, Stallings VA, Tullis DE, Zipf WB: Diagnosis, screening, and management of CFRD: a consensus conference report. Diabetes Res Clin Pract 1999; 45: 55– 71
    1. Sims EJ, Green MW, Mehta A: Decreased lung function in female but not male subjects with established cystic fibrosis-related diabetes. Diabetes Care 2005; 28: 1581– 1587

Source: PubMed

3
Abonner